| Literature DB >> 32522737 |
Min Liu1, Shou-Zhen Cheng1, Ke-Wei Xu2, Yang Yang3, Qing-Tang Zhu1, Hui Zhang1, Da-Ya Yang1, Shu-Yuan Cheng1, Han Xiao4, Ji-Wen Wang2, He-Rui Yao2, Yu-Tian Cong3, Yu-Qi Zhou3, Sui Peng1, Ming Kuang1, Fan-Fan Hou5, K K Cheng6, Hai-Peng Xiao4.
Abstract
OBJECTIVE: To examine the protective effects of appropriate personal protective equipment for frontline healthcare professionals who provided care for patients with coronavirus disease 2019 (covid-19).Entities:
Mesh:
Year: 2020 PMID: 32522737 PMCID: PMC7284314 DOI: 10.1136/bmj.m2195
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Demographic and baseline characteristics of study participants, control healthcare professionals with no history of exposure, and patients who had recovered from covid-19. Values are numbers unless stated otherwise
| Characteristics | Frontline healthcare professionals | Control healthcare professionals (n=77) | Patients recovered from covid-19 (n=80) | ||
|---|---|---|---|---|---|
| Total (n=420) | Doctors (n=116) | Nurses (n=304) | |||
| Sex: | |||||
| Male | 134 | 88 | 46 | 39 | 43 |
| Female | 286 | 28 | 258 | 38 | 37 |
| Average age (years) | 35.8 | 42.2 | 33.4 | 57.8 | 60.6 |
| Virus RNA | 0 | 0 | 0 | N/A | 80 |
| IgM | 0 | 0 | 0 | 0 | 24 |
| IgG | 0 | 0 | 0 | 0 | 80 |
| Exposure: | |||||
| AGPs (%) | 100* | 100 | 100 | 0 | N/A |
| Non-AGPs (%) | 100 | 100 | 100 | 0 | N/A |
| Patients with severe disease (%) | 80-85 | 80-85 | 80-85 | 0 | N/A |
| Patients with critical disease (%) | 10-15 | 10-15 | 10-15 | 0 | N/A |
| Working hours: | |||||
| Shifts (h/shift) | 4-6 | 8 | N/A | ||
| Work days (per week) | 5.4 | 5 | N/A | ||
| Intensive care unit (h/week) | 16.2 | 0 | N/A | ||
AGP=aerosol generating procedure; covid-19=coronavirus disease 2019; N/A=not applicable.
100% means that all healthcare professionals performed at lease one AGP or non-AGP procedure.
Personal protective equipment provided to study participants for prevention of covid-19
| Personal protective equipment | Ward* | AGP† exposure | ||||
|---|---|---|---|---|---|---|
| Intensive care units | Regular wards | No covid-19 contact area | AGPs | Non-AGPs | ||
| Mask: | ||||||
| N95 respirator | + | + | - | + | + | |
| Surgical mask | + | + | + | + | + | |
| Medical suit | + | + | - | + | + | |
| Isolation gown | + | + | - | + | + | |
| Apron | - | - | - | + | - | |
| Gloves | + | + | - | + | + | |
| Eye protection | + | + | - | + | + | |
| Hair cover | + | + | - | + | + | |
AGP=aerosol generating procedure; covid-19=coronavirus disease 2019.
Overlap existed between the different wards.
Powered air purifying respirator used when performing tracheal intubation.
Aerosol generating procedures performed by healthcare professionals. Values are numbers (percentages)
| Aerosol generating procedures | Cumulative procedures performed by doctors (n=116) | Cumulative procedures performed by nurses (n=304) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | <10 | 10-20 | >20 | 0 | <10 | 10-20 | >20 | ||
| Tracheal intubation* | 53 (45.7) | 43 (37.1) | 14 (12) | 6 (5.2) | 304 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Ventilation | 18 (15.5) | 67 (57.8) | 22 (19) | 9 (7.7) | 77 (25.3) | 138 (45.4) | 62 (20.4) | 27 (8.9) | |
| Gastric intubation | 116 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 156 (51.3) | 141 (46.4) | 7 (2.3) | 0 (0.0) | |
| Sputum aspiration | 116 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 61 (20) | 127 (41.8) | 116 (38.2) | |
| Aerosol inhalation | 116 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 107 (35.2) | 116 (38.2) | 34 (11.2) | 47 (15.4) | |
| Oral care | 116 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 83 (27.3) | 120 (39.5) | 68 (22.4) | 33 (10.8) | |
| Tracheostomy care | 116 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 88 (29) | 135 (44.4) | 52 (17.1) | 29 (9.5)) | |
Combined tracheostomy and intubation.
Fig 1Serological response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Concentrations of SARS-CoV-2 specific IgM and IgG antibodies in serum samples of healthcare professionals who had been exposed to coronavirus disease 2019 (covid-19) in Wuhan were quantified by chemiluminescence immunoassay (n=420). Serum samples from healthcare professionals without covid-19 exposure were used as negative controls (n=77). Serum samples from patients who had recovered from covid-19 were used as positive controls (n=80). Data are expressed as mean±standard deviation. Reference specified by manufacturer (<10 AU/mL)